Petros Pharmaceuticals, Inc. Operating Lease, Payments
Petros Pharmaceuticals, Inc. (PTPI) reported Operating Lease, Payments of $155.24 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2023-12-31 was $47.70K, a 1.63% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2023-09-30 was $47.23K, a 0.62% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2023-06-30 was $47.23K, a 0.62% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2023-03-31 was $47.23K, a 0.62% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, payments for fiscal 2024 was $155.24K, a 18.02% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. operating lease, payments for fiscal 2023 was $189.37K, a 0.87% increase from fiscal 2022.
- Petros Pharmaceuticals, Inc. operating lease, payments for fiscal 2022 was $187.74K, a 1.90% increase from fiscal 2021.
- Petros Pharmaceuticals, Inc. operating lease, payments for fiscal 2021 was $184.24K, a 0.88% increase from fiscal 2020.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 6 month as first filed | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $155.24K 10-K · filed 2025-03-31 | ||||
| 2023-12-31 | $47.70K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $94.92K derived: sum of 2 quarters · filed 2025-03-31 | $142.15K derived: sum of 3 quarters · filed 2025-03-31 | $189.37K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $47.23K 10-Q · filed 2023-11-15 | $94.45K derived: sum of 2 quarters · filed 2023-11-15 | $141.68K 10-Q · filed 2023-11-15 | $188.61K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2023-06-30 | $47.23K 10-Q · filed 2023-08-14 | $94.45K 10-Q · filed 2023-08-14 | $141.39K derived: sum of 3 quarters · filed 2024-04-01 | $188.32K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2023-03-31 | $47.23K 10-Q · filed 2023-05-15 | $94.16K derived: sum of 2 quarters · filed 2024-04-01 | $141.09K derived: sum of 3 quarters · filed 2024-04-01 | $188.03K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2022-12-31 | $46.93K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $93.87K derived: sum of 2 quarters · filed 2024-04-01 | $140.80K derived: sum of 3 quarters · filed 2024-04-01 | $187.74K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $46.94K 10-Q · filed 2023-11-15 | $93.87K derived: sum of 2 quarters · filed 2023-11-15 | $140.81K 10-Q · filed 2023-11-15 | $187.22K derived: sum of 4 quarters · filed 2023-11-15 | |
| 2022-06-30 | $46.94K 10-Q · filed 2023-08-14 | $93.87K 10-Q · filed 2023-08-14 | $140.28K derived: sum of 3 quarters · filed 2023-08-14 | $186.22K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $46.94K 10-Q · filed 2023-05-15 | $93.35K derived: sum of 2 quarters · filed 2023-05-15 | $139.29K derived: sum of 3 quarters · filed 2023-05-15 | $185.23K derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $46.41K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $92.36K derived: sum of 2 quarters · filed 2023-03-31 | $138.30K derived: sum of 3 quarters · filed 2023-03-31 | $184.24K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $45.94K 10-Q/A · filed 2022-11-15 | $91.88K derived: sum of 2 quarters · filed 2022-11-15 | $137.83K 10-Q/A · filed 2022-11-15 | $183.49K derived: sum of 4 quarters · filed 2022-11-15 | |
| 2021-06-30 | $45.94K 10-Q · filed 2022-08-12 | $91.84K 10-Q · filed 2022-08-12 | $91.88K 10-Q · filed 2021-08-16 | $137.54K derived: sum of 3 quarters · filed 2022-08-12 | $183.20K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $45.94K 10-Q · filed 2022-05-16 | $91.60K derived: sum of 2 quarters · filed 2022-05-16 | $137.26K derived: sum of 3 quarters · filed 2022-05-16 | $182.30K derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | $45.66K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $91.32K derived: sum of 2 quarters · filed 2022-03-31 | $136.36K derived: sum of 3 quarters · filed 2022-03-31 | $182.64K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $45.66K 10-Q · filed 2021-11-15 | $90.70K derived: sum of 2 quarters · filed 2021-11-15 | $136.98K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $45.04K 10-Q · filed 2021-08-16 | $91.32K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $45.66K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |